5.75
-0.112(-1.91%)
Currency In USD
| Previous Close | 5.86 |
| Open | 5.8 |
| Day High | 5.86 |
| Day Low | 5.57 |
| 52-Week High | 14.36 |
| 52-Week Low | 4.59 |
| Volume | 4,632 |
| Average Volume | 22,217 |
| Market Cap | 11.01M |
| PE | -0.22 |
| EPS | -26.42 |
| Moving Average 50 Days | 5.39 |
| Moving Average 200 Days | 7.14 |
| Change | -0.11 |
If you invested $1000 in Bolt Biotherapeutics, Inc. (BOLT) since IPO date, it would be worth $8.94 as of October 19, 2025 at a share price of $5.751. Whereas If you bought $1000 worth of Bolt Biotherapeutics, Inc. (BOLT) shares 3 years ago, it would be worth $201.08 as of October 19, 2025 at a share price of $5.751.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
GlobeNewswire Inc.
Oct 01, 2025 8:05 PM GMT
Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire Inc.
May 08, 2025 12:00 PM GMT
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the tre
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
GlobeNewswire Inc.
Apr 30, 2025 8:05 PM GMT
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April